

Late-life onset psychosis-like symptoms assessed in the Mild Behavioural Impairment framework are associated with impaired performance on the Stroop task

Byron Creese^{1,2}, Olly Gibbs², Ellie Moodie², Adam Hampshire⁴, Anne Corbett³, Zahinoor Ismail^{3,5}

¹Division of Psychology, Department of Life Sciences, Brunel University London, UK

²Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, UK

³Department of Health and Community Sciences, Faculty of Health and Life Sciences, University of Exeter, UK

⁴Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK

⁵Departments of Psychiatry, Clinical Neurosciences, Community Health Sciences, and Pathology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

<https://doi.org/10.52732/EHBP8068>

ABSTRACT

Late-life onset psychosis and milder delusion-like ideation are known risk factors for cognitive decline and dementia. The Mild Behavioural Impairment (MBI) framework was developed to capture specific psychotic-like symptoms relevant to dementia prognosis in older adults. This study aims to investigate the cognitive deficits associated with MBI-psychosis and their implications for understanding the underlying mechanisms and potential treatment targets. The study recruited participants between November 2021 and July 2022 from the PROTECT study registry. Participants completed the Cambridge Gambling Task, Stroop, Trail Making, Paired Associates Learning, Verbal Reasoning, Digit Span and Self-Ordered Search. Psychotic symptom status was assessed using the Mild Behavioural Impairment Checklist (MBI-C), with participants categorized as MBI-psychosis if they or their study partner reported any psychotic symptoms. Out of 2,109 eligible participants invited, 416 consented to participate. There were no significant differences in age, sex, education level, or mental health history between the MBI-psychosis and No Psychosis groups. Participants with MBI-psychosis exhibited significantly worse performance on the Stroop task (adjusted $p=0.0007$, Cohen's $d=0.37$) compared to those without

This article is part of the Special Issue 'From normal aging to Alzheimer's disease: an interdisciplinary exploration of causes, prevention, diagnostic and treatment' supported by France Alzheimer.

Peer Reviews: The peer review reports are published alongside the article.

Received 4 Dec. 2023
Revised 02 May. 2024
Published 24 May. 2024 (v2)



This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits



psychosis. There was also some evidence of impairment in verbal reasoning, though it did not reach significance after Bonferroni correction. No significant differences were found on other cognitive measures. This cross-sectional study provides insight into the cognitive deficits associated with MBI-psychosis. The finding of impaired Stroop task performance in individuals with MBI-psychosis is noteworthy, as this deficit is commonly observed in earlier-life major psychotic disorders. Further research is needed to explore the neural underpinnings of these deficits and to determine whether they represent early markers of neurodegenerative disease.

Keywords: Mild Behavioural Impairment, psychosis, Stroop, Cambridge Gambling Task, executive function.

INTRODUCTION

Late-life onset psychosis and milder delusion-like ideation are established risk factors for cognitive decline and dementia, even in people with no prior history of psychotic disorders[1][2][3]. The Mild Behavioural Impairment (MBI) framework was developed to capture the specific spectrum of symptoms that are relevant to dementia prognostication in older adults[4][5]. When psychotic symptoms are described in this context, we refer to them here as MBI-psychosis. MBI is an evolving framework and we acknowledge that Very Late Onset Schizophrenia-Like Psychosis (VLOSLP) may, for some, reflect prodromal dementia[6]. However, it is important to note that here we are not referring to a clinical disorder but milder changes in thoughts and perceptions, typically defined by non-systematised suspicious thoughts about others. Grandiose delusions and hallucinations in any modality are virtually absent in MBI-psychosis[7]. In addition to psychosis, MBI also captures the domains of apathy, affective symptoms, impulse dyscontrol and socially inappropriate behaviour. MBI-psychosis is the least common of the five MBI domains, present in 1-5% of cognitively normal people[7][8].

Risk of global cognitive impairment and incident dementia associated with MBI-psychosis is the highest of the five MBI domains[3]. This risk warrants a detailed understanding of the symptom profile, but studies are limited due to the fact that symptoms are uncommon (so large-scale screening is needed to identify people) or often framed in the context of psychiatric disorders such as Late Onset Schizophrenia (LOS) and VLOSLP. The cognitive profiles of LOS and VLOSLP, along with earlier life psychoses are well described; deficits in working memory, language, visuospatial ability and attention are commonly observed across all[9][10]. Tests which have been commonly used to elucidate these impairments include Stroop, Trail Making and the Cambridge Gambling Task[11][12][13].

A detailed understanding of the cognitive substrates of MBI-psychosis will lead to a better understanding of the transdiagnostic mechanisms underlying symptoms, which may guide possible psychological treatment targets to mitigate risk of cognitive decline and perhaps the emergence of more severe psychoses in dementia. In addition to possible transdiagnostic

mechanisms, understanding differences in cognitive substrates may provide clearer differentiation from late-life psychotic disorders such as VLOSLP, which could be important when determining whether psychotic symptoms are due to neurodegeneration or are functionally psychiatric in their aetiology.

Our online longitudinal study of community dwelling adults over 50 has MBI data from over 20,000 people and is to our knowledge the largest sample in the world with these measurements. In this sample, we have previously shown longitudinal changes in cognition associated with psychosis, but these studies were largely focused on memory[1][14]. While undoubtedly an important domain in the field of psychosis, it is not known if people with MBI-psychosis exhibit the broader range of cognitive deficits associated with psychosis in clinical contexts in early or late-life.

In this study we tested the hypothesis that participants with MBI-psychosis would exhibit impairment on Stroop, Trail Making and the Cambridge Gambling Task compared to participants without MBI-psychosis.

METHODS

Study period

Recruitment took place between November 2021 and July 2022.

PROTECT registry:

Participants were identified from the PROTECT study registry. Launched in 2015, PROTECT is an online study with the principal aim of determining risk factors for cognitive aging and dementia. Participants volunteered in response to local and national publicity linked to the NIHR South London and the Maudsley Biomedical Research Centre, and the University of Exeter. People enrolled in PROTECT complete annual demographic, medical, mental health, and lifestyle questionnaires. They also complete an annual detailed cognitive test battery that focuses on domains pertinent to dementia risk (memory, attention, reasoning, and executive function)[15]. Informed consent to enrolling into PROTECT is obtained online and all participants give consent to be contacted for future research (Research Ethics Committee reference number 13/LO/1578). Participants may nominate a study partner who is required to know the participant well for at least 10 years. Upon enrolment into the PROTECT registry, participants confirm that they do not have a diagnosis of dementia, do have access to a computer and the internet, are age 50 years or older, and are able to read and write English.

Ethics

An additional ethical review and approval was obtained for this study, covering completion of the Cambridge Gambling Task which is not part of the core PROTECT study battery (University of Exeter College of Medicine and Health Research Ethics Committee, reference number: 19/11/231).

Measures

Demographic and medical history

Demographic data and medical history were collected by self-report questionnaire. Data from the PROTECT annual assessment closest to recruitment start were used. Self-reported medical history and social activities (drawn from the CHAMPS questionnaire[16]) were also available. Self-reported history of diagnosis of any of the following psychiatric/mental health conditions was also recorded: depression, mania/bipolar depression, anxiety/generalized anxiety disorder, social anxiety disorder, agoraphobia, panic attacks, obsessive compulsive disorder, anorexia nervosa, bulimia nervosa, binge eating, schizophrenia, any other type of psychotic illness, personality disorder, autism spectrum disorder, attention-deficit/hyperactivity disorder, gambling and addiction. The presence of schizophrenia or any other psychotic disorder, addiction and gambling were used as exclusion criteria (see below) and the remaining were coded collectively as 'history of a mental health condition'.

MBI-psychosis

Psychotic symptom status was ascertained from the Mild Behavioural Impairment Checklist (MBI-C), which has been validated for online use. Both participants and their study partners provided ratings[4][7]. A total of 34 questions captures symptoms in five domains (mood, apathy, impulse dyscontrol, social inappropriateness, and psychosis). Each item is first rated as present or absent; if rated present, the severity of the item is then scored on a scale of 1 to 3.

To reflect MBI diagnostic criteria, the MBI-C is prefixed with the following instructions to participants (with wording amended accordingly for study partner ratings): "We would like to know if there have been any subtle changes in your behaviour such as changed interest in activities, altered mood, or impulsive behaviour." Answer options for the questions are as follows: "Yes: the behaviour has been present for at least 6 months (continuously, or on and off) and is a change from your longstanding pattern of behaviour. No: behaviour not present, or present for less than 6 months, no change from usual behaviour. Mild: noticeable, but not a significant change. Moderate: significant, but not a dramatic change. Severe: very marked or prominent, a dramatic change."

There are five MBI-C questions pertaining to psychosis; three questions cover delusion-type experiences, which includes overvalued ideas (paranoid, harm, and grandiose-type), and two cover hallucinations (visual and auditory). Ratings of participants and study partners had to be within 6 months of each other. Based on these ratings, two groups were created: MBI-psychosis

and No Psychosis. Participants were classified as MBI-psychosis if they or their study partner rated any of the five psychosis items as present at their first visit. Participants were coded as No Psychosis if they scored zero on all five items on both participant and study partner ratings.

Cognitive tests

Cross-sectional cognitive test results were drawn both from existing tests completed via participation in the PROTECT study and new testing (Cambridge Gambling Task, CGT) specifically for the present study.

PROTECT Cognitive Test Package (CTP): Test results on Trail Making and Stroop were made available from PROTECT. For context we also included other tests which have been studied previously in relation to MBI-psychosis[14]: Paired Associates Learning, Digit Span, Self-Ordered Search, Verbal Reasoning. Paired Associates Learning, Digit Span, Self-Ordered Search and Verbal Reasoning were from a validated battery designed at the Medical Research Council Cognition and Brain Sciences Unit[17]. Stroop and Trail-Making are simply online versions of the well-established neuropsychological tests. Technical validation of all tests was undertaken during development and coding, which involved checking responses by the computer against a manual record of actual responses.

Paired Associates Learning, Digit Span, Self-Ordered Search and Verbal Reasoning were introduced to PROTECT in 2015, while Trail Making and Stroop were introduced in 2019 (see Box 1).

Box 1 - PROTECT Cognitive Test Package

Cognitive test	Description
Paired Associates Learning	A series of objects appear in the cells on screen. Participants are instructed to remember the cell in which the object appears. When an object appears at the bottom centre, the participant is instructed to click on the cell in which they recall seeing that object. The participant is given three attempts at each level.
Digit Span	Participants are required to recall strings of digits presented visually. Uses a ratchet-style approach in which each successful trial is followed by a new sequence that is 1 digit longer than the last and each unsuccessful trial is followed by a new sequence that is 1 digit shorter than the last.
Self-ordered Search	A series of boxes are present on the screen, one of the boxes will contain a diamond. The participant selects each box until they locate the diamond. The diamond is then placed in another box and again the volunteer must locate it, but they must be careful not to select the box in which the diamond was previously found.
Verbal Reasoning	A sentence is displayed at the bottom of the screen whilst a square and a circle are displayed above. The participant needs to respond true or false as to whether the sentence correctly describes the configuration of the circle and square. Participants are given three minutes to solve as many problems as they can.
Trail Making	Comprises two parts: Part A, where participants connect numbered circles in ascending order, and Part B, where participants connect alternating numbers and letters in sequential order (1-A-2-B-3-C, etc.).
Stroop	Participants are presented with a list of color names (e.g., red, blue, green) printed in incongruent ink colours (e.g., the word "red" printed in blue ink) or congruent colours. Participants are asked to name the ink color while ignoring the written word.

Cambridge Gambling Task (CGT, Cambridge Cognition Ltd.): This cognitive task evaluates decision-making and risk-taking behaviour in a non-learning context. On the screen, participants are presented with a row of ten boxes, some coloured red and others blue. The ratio of red to blue boxes changes between stages, but there is always one box containing a yellow token. The objective is to 'bet' on whether the yellow token is in a red or blue box. To make their choice, participants use 'Red' and 'Blue' buttons located at the bottom of the screen.

Participants begin with 100 points and decide how many of these points to wager on their choice. A circle at the centre of the screen displays the current bet value, which can either incrementally increase or decrease, depending on the chosen task variant. When this circle reaches the desired proportion of their score to bet, participants press the button, and their points are either added or deducted from their total score, based on the correctness of their choice and the actual location of the token. The following six CGT outcome measures were analysed in this study: 1. Decision making quality. 2. Risk adjustment. 3. Delay aversion. 4. Risk taking. 5. Median time to decision. 6. Overall proportion of points bet.

Inclusion/exclusion criteria

The PROTECT database was screened for participants meeting the following criteria (these data were available via PROTECT and were not collected during the present study).

Inclusion criteria

- Active participant in the PROTECT study in the two years prior to the start of the study period (to ensure only those who are engaged in the platform are approached).
- Aged 50 or over.
- Have reported yes to experiencing any of questions 5.1, 5.2 or 5.3 on the Mild Behavioural Impairment Checklist questionnaire or no to all of these questions (this will determine the experimental groups).
- Has nominated a study partner who has also answered the above questions.
- Self and study partner MBI-C ratings are completed within one year of each other.

Exclusion criteria

- Diagnosis of dementia or neurodegenerative disease.
- Diagnosis of stroke or Mild Cognitive Impairment.
- Diagnosis of psychotic disorder (including schizophrenia), as our aim was to focus specifically on later-life psychosis that is not explained by other psychotic disorders (per the MBI criteria).
- History of problem gambling (because the task was done unsupervised and involves a gambling game, we applied this criterion to minimise the likelihood participant harm).
- History of addiction to any substance (rationale as per gambling exclusion).

Target sample size

Our sample size of 416 has >80% power to detect a standardised mean difference (Cohen's d) of at least 0.4 between the MBI-psychosis and No Psychosis groups at a Bonferroni-corrected $p=0.004$ ($0.05/12$; the eight primary cognitive test comparisons plus the four secondary cognitive tests).

Recruitment procedure

Consent was obtained online within each eligible participant's account on the PROTECT UK platform. Briefly:

1. Eligible participants were sent an email explaining that they are suitable for a new study and that the study documents are available to review in their account.
2. Participants then enter the PROTECT account where they can view the Participant Information Sheet (PIS). The information sheet is presented in a printable format, and study participants were required to tick a box to confirm they had read and understood the relevant document.
3. Participants were then presented with a new website page with each consent item in the Informed Consent Form (ICF). They had to tick each item individually which activates a button to allow them to proceed to a new website page.
4. On the new website page, participants then had to tick a further box to confirm they consent to take part in the study which activates a button that they must select to continue. This process ensures consent cannot be given in error.
5. Consents were time- and date-stamped electronically and stored on the PROTECT study database, linked to study ID and pseudo-anonymised to allow for linkage to personal details in the event this information is required for future contact.
6. Once consent was given, participants were automatically sent a URL which connected them with Cambridge Cognition's website where they completed the CGT.

Eligible participants were grouped as follows: No Psychosis, self-rated MBI-psychosis only, proxy-rated MBI-psychosis only or both self- and proxy-rated MBI-psychosis. Email invitations were randomly sent out in batches with an approximately equal distribution across four groups, and on age, sex and education level and mental health history to balance recruitment.

Analysis

All cognitive test scores were centred to a mean of zero and standard deviation of 1 before analysis. The mean scores on each of the 6 PROTECT cognitive tests and the 6 CGT outcomes were compared between MBI-psychosis and No Psychosis. CGT Overall Proportion Bet, CGT Risk Taking and Verbal Reasoning were all normally distributed so an independent samples t -test was used. The Mann-Whitney U test was used for all remaining cognitive tests due to evidence of non-normal distributions. The Kruskal-Wallis test was used for self and proxy group comparisons for the non-normally distributed tests and one-way ANOVA was used for normally

distributed tests. To adjust for covariates (see Tables 2 and 4), variables were regressed out of the cognitive test scores and statistical tests (as described above) were performed on the residuals. Prior to this, employment status (retired, self-employed and unemployed) were first dummy coded. Correlations between total MBI-psychosis score (the sum score of the five psychosis items ranging from 0 to 15) and cognitive test scores were done using the Spearman's rank correlation test. Effect sizes are expressed as Cohen's *d* and Bonferroni-corrected $p=0.004$ was used.

RESULTS

2,109 recruitment invitations were sent to eligible participants between November 2021 and July 2022. Of these, 416 consented to the study online, completed the CGT task and had recent PROTECT cognitive test data. There were no major differences between those who completed the study and those who were invited but did not consent ([Supplementary Table 1](#)). There was a statistically significant, though modestly, higher proportion of those who participated reporting that they 'never' saw family on CHAMPS questionnaire compared with those who did not participate (27% vs 23%). Participant characteristics are shown in Table 1. Most characteristics were comparable between the two groups. People with MBI-psychosis were, however, more likely to be retired, self-employed or unemployed. There were no statistically significant differences in age, sex, education level or mental health history between the MBI-Psychosis and No Psychosis groups.

Table 2 - Participant characteristics.

¹Proportions tested with chi-square or Fisher's exact test; means tested with t-test

	No Psychosis		MBI-Psychosis		p ¹
N	178		238		
Sex (N, %)					
Male	48	27	57	24	1
Female	130	73	181	76	
Age (mean, SD)					
	68	7	68	6	1
Education level (N, %)					
GCSE (left school at 16)	21	12	27	11	1
A-Level (left school at 18)	18	10	27	11	
Vocational Qualification	25	14	45	19	
Undergraduate Degree	66	37	91	38	
Postgraduate Degree	37	21	39	16	
Doctorate	11	6	9	4	
Ethnicity (N, %)					
Asian	1	1	2	1	1
Black	0	0	0	0	
White	177	99	235	99	
Mixed	0	0	1	0	
Employment status (N, %)					
Employed full time	24	13	24	13	0.02
Employed part-time	37	21	33	19	
Self-employed	9	5	29	16	
Retired	102	57	137	77	
Unemployed	6	3	15	8	
Marital status (N, %)					
Married	136	76	171	96	0.40
Widowed	7	4	15	8	
Separated	0	0	2	1	
Divorced	8	4	21	12	
Civil partnership	2	1	2	1	
Co-habiting	11	6	12	7	
Single	14	8	15	8	
History of any mental health condition (N, %)					
No	99	56	121	51	0.40
Yes	79	44	117	49	
Medical co-morbidities (N with condition, %)					
Hypertension	46	26	57	24	1
Heart disease/heart attack/ang	6	3	4	2	0.43
Diabetes	3	2	8	3	0.46
High cholesterol	12	7	28	12	0.12
Hypothyroidism	4	2	5	2	1
Hyperthyroidism	1	1	1	0	1
Arthritis	14	8	16	7	1
Cancer (current)	1	1	0	0	1
Cancer (full remission)	4	2	2	1	0.44
Osteoporosis	0	0	1	0	1
Asthma	4	2	2	1	0.40
Epilepsy	3	2	2	1	1
Paget's disease	0	0	0	0	-
Deep vein thrombosis	0	0	3	1	0.36
HIV	0	0	0	0	-
AIDS	0	0	0	0	-
Hepatitis C	0	0	0	0	-
Social Activities ("How many times a week do you..."; (N, %))					
Visit friends					
Never	48	27	65	27	1
Once	74	42	101	42	
More than once	56	31	72	30	
Go to a community centre or group					
Never	136	76	182	76	1
Once	23	13	30	13	
More than once	19	11	26	11	
Do voluntary work					
Never	99	56	150	63	0.07
Once	41	23	57	24	
More than once	38	21	31	13	
Attend church or take part in church activities					
Never	141	79	203	85	0.10
Once	26	15	19	8	
More than once	11	6	16	7	
Attend a club or other group meetings					
Never	115	65	157	66	1
Once	41	23	50	21	
More than once	22	12	31	13	

Cognitive testing

Results of the primary analysis comparing MBI-psychosis to No psychosis are shown in Table 3. The MBI-psychosis group had significantly worse performance on the Stroop task (unadjusted p -value=0.0002; adjusted for employment status=0.0007; Cohen's d =0.37). There was evidence of a smaller impairment on verbal reasoning but this did not pass Bonferroni correction. There were no other significant differences across any of the other outcomes. There was also a statistically significant but modest correlation between sum score across the five MBI-C psychosis items (ranging from 0 to 15) and scores on these two tests (Stroop: ρ =-0.18, p =0.0001; Verbal Reasoning: ρ =-0.13, p =0.0007).

Table 3 - Cognitive test scores, MBI-Psychosis vs No Psychosis.

¹Risk Taking, Overall Proportion Bet and Verbal Reasoning tested with t-test, all others with Mann-Whitney U test

²Tests performed on cognitive scores adjusted for employment status

	No Psychosis		MBI-Psychosis		Cohen's d		95% CI		P _{unadjusted} ¹	P _{adjusted} ^{1,2}
N	178		238		-		-		-	
CGT (mean, sd)										
Decision Making Quality	0.08	0.98	-0.06	1.01	0.14	-0.34	-	0.05	0.1	0.2
Risk Adjustment	-0.01	0.95	0.01	1.04	0.01	-0.18	-	0.21	0.6	0.9
Delay Aversion	-0.06	1.09	0.05	0.93	0.11	-0.08	-	0.31	0.5	0.6
Risk Taking	0.04	0.99	-0.03	1.01	0.07	-0.26	-	0.13	0.5	0.5
Median Time to Decision	-0.06	0.89	0.05	1.08	0.11	-0.09	-	0.3	0.6	0.8
Overall Proportion Bet	0.05	1	-0.04	1	0.09	-0.28	-	0.11	0.4	0.4
PROTECT CTP (mean, sd)										
Digit Span	0	0.92	0	1.06	0.01	-0.19	-	0.2	0.7	0.7
Paired Associates Learning	-0.04	1.02	0.03	0.98	0.07	-0.13	-	0.26	0.5	0.3
Verbal Reasoning	0.14	1	-0.11	0.99	0.25	0.06	-	0.45	0.01	0.02
Self-Ordered Search	0.04	1.03	-0.03	0.98	0.06	0.13	-	0.26	0.2	0.2
Stroop	0.21	1	-0.16	0.97	0.37	0.18	-	0.57	0.0002	0.0007
Trail Making	-0.08	0.99	0.06	1.01	0.14	0.06	-	0.33	0.07	0.06

Self and proxy report MBI-psychosis

Post-hoc, we then explored whether there were differences between respondent types, results from this analysis are displayed in Table 4 along with the participant characteristics split by group. Two subgroups were created from the MBI-Psychosis group, one where symptoms were rated present by self-report and absent on proxy report and one where symptoms were rated present on proxy report and absent on self-report. We excluded the group where both self and proxy were present ($n=43$) as our primary interest was differences between the two. The No Psychosis reference group remained the same (i.e., both self and proxy ratings were 0). In this analysis there were no between group differences on Verbal Reasoning, however performance on the Stroop task was worse in both self only and proxy only groups in comparison to the No Psychosis group ($H=11.47$, $df=2$, $p=0.003$). A significantly larger proportion of people with self-reported MBI-psychosis had high cholesterol (18% vs 7% for proxy-reported MBI-psychosis and 7% for No Psychosis). Cognitive scores were therefore adjusted for both employment status and history of high cholesterol, which did attenuate the findings. Adjusted mean scores for MBI-Psychosis self, MBI-psychosis proxy and No Psychosis were -0.13, -0.15 and 0.16 respectively for Stroop ($p=0.02$) and -0.09, -0.10 and 0.10 respectfully for Verbal Reasoning ($p=0.2$).

There were no differences in performance by respondent type for of the CGT outcomes or for Trail making (Supplementary Table 2).

Table 4- Participant characteristics, Stroop and verbal reasoning scores by self and proxy-rated MBI-Psychosis.

¹Proportions tested with chi-square or Fisher's exact test means with one-way ANOVA; Verbal Reasoning tested with one-way ANOVA, Stroop with Kruskal-Wallis test
²Tests performed on cognitive scores adjusted for employment status and high cholesterol diagnosis

	No Psychosis		MBI-Psychosis Self Only		MBI-Psychosis Proxy Only		P _{unadjusted} ¹	P _{adjusted} ^{1,2}
N	178		85		110		-	
Sex (N, %)								
Male	48	27	29	34	20	18	0.04	-
Female	130	73	56	66	90	82		
Age (mean, sd)	68	6.8	68	7	68	5.7	0.9	-
Education Level (N, %)								
GCSE (left school at 16)	21	12	8	9	13	12	0.8	-
A-Level (left school at 18)	18	10	11	13	9	8		
Vocational Qualification	25	14	13	15	22	20		
Undergraduate Degree	66	37	38	45	39	35		
Postgraduate Degree	37	21	12	14	22	20		
Doctorate	11	6	3	4	5	5		
Ethnicity (N, %)								
Asian	1	1	1	1	1	1	1	-
Black	0	0	0	0	0	0		
White	177	99	84	99	108	98		
Mixed	0	0	0	0	1	1		
Employment status (N, %)								
Employed full time	24	13	9	11	11	10	0.1	-
Employed part-time	37	21	10	12	16	15		
Self-employed	9	5	6	7	18	16		
Retired	102	57	55	65	58	53		
Unemployed	6	3	5	6	7	6		
Marital status (N, %)								
Married	136	76	59	69	84	76	0.4	-
Widowed	7	4	7	8	6	5		
Separated	0	0	1	1	1	1		
Divorced	8	4	5	6	10	9		
Civil partnership	2	1	0	0	2	2		
Co-habiting	11	6	7	8	2	2		
Single	14	8	6	7	5	5		
History of Non-Psychosis Any Mental Health Condition (N, %)								
No	99	56	45	53	63	57	0.8	-
Yes	79	44	40	47	47	43		
Medical co-morbidities (N with condition, %)								
Hypertension	46	26	61	72	89	81	0.4	-
Heart disease/heart attack/a	6	3	3	4	1	1	0.4	-
Diabetes	3	2	3	4	2	2	0.2	-
High cholesterol	12	7	15	18	8	7	0.03	-
Hypothyroidism	4	2	1	1	4	4	0.5	-
Hyperthyroidism	1	1	0	0	1	1	0.8	-
Arthritis	14	8	6	7	6	5	0.8	-
Cancer (current)	1	1	0	0	0	0	0.7	-
Cancer (full remission)	4	2	2	2	0	0	0.3	-
Osteoporosis	0	0	1	1	0	0	0.3	-
Asthma	4	2	0	0	1	1	0.5	-
Epilepsy	2	1	1	1	0	0	0.6	-
Paget's disease	0	0	0	0	0	0	0.7	-
Deep vein thrombosis	0	0	1	1	0	0	0.009	-
HIV	0	0	0	0	0	0	-	-
AIDS	0	0	0	0	0	0	-	-
Hepatitis C	0	0	0	0	0	0	-	-
Social Activities ("How many times a week do you...": (N, %)								
Visit friends								
Never	48	27	25	29	16	15	0.3	-
Once	74	42	35	41	20	18		
More than once	56	31	25	29	7	6		
Go to a community centre or group								
Never	136	76	66	78	36	33	0.9	-
Once	23	13	11	13	4	4		
More than once	19	11	8	9	3	3		
Do voluntary work								
Never	99	56	51	60	72	65	0.4	-
Once	41	23	21	25	26	24		
More than once	38	21	13	15	12	11		
Attend church or take part in church activities								
Never	141	79	70	82	98	89	0.3	-
Once	26	15	8	9	6	5		
More than once	11	6	7	8	6	5		
Attend a club or other group meetings								
Never	115	65	56	66	34	31	0.6	-
Once	41	23	18	21	5	5		
More than once	22	12	11	13	4	4		
Cognitive Tests (mean, sd)								
Verbal Reasoning	0.14	1.01	-0.12	1.1	-0.04	0.91	0.1	0.2
Stroop	0.21	1	-0.16	1.01	-0.13	0.94	0.003	0.02

Specificity

Finally, we examined how specific the association between MBI-psychosis and Stroop performance by examining scores in people with MBI affective/mood symptoms. We split the same according to whether they or their proxy endorsed any of the six items of the MBI-C scale that cover mood/anxiety symptoms (there is only limited evidence that non-clinical affective symptoms, e.g., dysphoria, are linked to worse Stroop performance in the broader literature[18]). There were 233 participants with MBI-mood and 183 without. MBI-psychosis and MBI-mood were strongly related (68% of MBI-psychosis participants had MBI-mood, compared with 31% of No Psychosis participants) however there was no difference in Stroop performance when the sample was stratified on MBI-mood status (means (sd): MBI-mood = -0.05 (1.01); No Mood = 0.06 (0.98); $p=0.26$).

DISCUSSION

In this cross-sectional study, we set out to gain a detailed understanding of the cognitive substrates of MBI-psychosis. We did this by comparing performance on the Cambridge Gambling Task, Trail Making and Stroop. We found that MBI-psychosis was associated with worse performance on the Stroop test but not on any of the other cognitive tests. The Stroop test association was specific to MBI-psychosis (we found no association with mood/anxiety symptoms).

MBI as a broad label (i.e., any of the five domains) is reliably associated with dementia and cognitive decline, as shown by a number of observational studies[15][19][20][21][22][23]. This study extends these findings to the specific domain of psychosis and a broader range of cognitive domains. People with MBI-psychosis performed worse on the Stroop task than those with No Psychosis. Similar deficits were observed for self-reported and proxy reported MBI-psychosis, reflecting the importance of capturing information from as wide a range of sources as possible[1][24][25]. Some evidence of worse performance on Verbal Reasoning was also found. We suspect a smaller effect size made our study underpowered to detect a difference on this test however we note it here because it is consistent with a previous larger study of which our sample was a part[14]. There were no differences on any of the other measures. There was no relationship between MBI-psychosis and any measure on the CGT, this is in contrast to deficits on this test being observed in earlier life psychoses[11][13]. This study was only powered to detect a medium effect size so it is possible that a small effect is present and that this would be observed in larger studies. Accordingly, it may be the case that deficits in impulse control, decision making and risk taking are only associated with more severe psychoses, while processing speed and selective attention (as measured by Stroop) are more widely observed with a larger effect size across the psychosis spectrum. Executive function deficits are robustly seen in VLOSLP and LOS (reviewed in[9]) and our findings suggest similar neuropsychological correlates in MBI-psychosis. One interesting point of difference is that memory deficits have

also been observed in VLOSLP, albeit inconsistently[9]. In a much larger study of longitudinal cognitive decline there was no evidence of a link between MBI-psychosis and verbal or spatial working memory[14]. It would be premature to conclude this as a robust point of difference in the neuropsychological profiles of VLOSLP and MBI-psychosis however it is plausible that more severe psychotic syndromes are accompanied by a broader range of cognitive deficits.

Studies of late-life psychosis-like symptoms (especially in non-clinical samples) are uncommon and to our knowledge this is the first demonstration of deficits on the Stroop task in the later-life onset syndrome of MBI-Psychosis. Further studies of the neural correlates of this finding are warranted however it is possible that the deficits observed here reflect impaired response inhibition and/or attention, which are both thought to be a key cognitive substrate of delusional ideation in earlier life psychoses as indicated in theoretical models and empirical data[26][27][28].

While there is evidence linking MBI-psychosis to incident dementia, we do not know anything about the aetiology in this sample. Further research should incorporate AD biomarkers to help elucidate in whom the symptoms represent sequelae of neurodegenerative disease and whether our findings linking Stroop still hold. Psychosis in syndromic dementia due to AD is associated with a significantly worse disease course so targeting the emergence of psychosis early on in the neurodegenerative cascade could bring considerable patient benefit later. Indeed, just as cognitive deficits on Stroop are seen in younger people at high risk of psychosis[29], it would be interesting to explore whether the same applies to people at risk of psychosis in Alzheimer's disease.

The limitations of this study include the online format, which entails remote unsupervised completion of questionnaires and cognitive tests in English. While this could lead to inaccuracies, people reporting MBI-psychosis are relatively few (as symptoms are rare) and hard to reach as they may not be in contact with clinical services. We also required a study partner to provide ratings and while this had led to a more detailed understanding of symptoms in those with a study partner we should acknowledge that this requirement could have biased our study sample. In addition, recruitment relies on participant self-selecting, no direct approaches are made, which may be one a reason for the overrepresentation of women and those with a higher education. There is active work being undertaken to address this imbalance in the PROTECT study but it is possible that the current findings are not generalisable to the general population. Coverage of functional impairments and socio-economic variables could be improved, for example there were no direct measures of loneliness or activities of daily living, and only a limited number of questions available related to social activities and employment status. Finally, all demographic and clinical history data were self-reported, introducing possible recall biases and inaccuracies. A strength of this study (by virtue of recruiting from a registry) is that we are able to determine that there are no meaningful differences in characteristics between those who accepted the invitation to participate and those who did not. Perhaps the most important

difference to highlight, albeit only modest, was that those who participated were more likely to never visit friends than those who did not participate (27% vs 23%).

In summary, we show for the first time links between MBI-psychosis and impaired Stroop performance, which may reflect response inhibition, a key cognitive substrate of delusional ideation.

STATEMENTS AND DECLARATIONS

Funding: This study was funded by an Alzheimer's Research UK South West Network grant and a generous donation by University of Exeter alumnus, Mr David Bays.

Acknowledgments: The authors are grateful to the participants for volunteering their time and to the PROTECT study team for supporting the study (Ellie Pickering, Megan Richards and Adam Bloomfield). This study was supported by the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This research was also supported by the NIHR Collaboration for Leadership in Applied Health Research and Care South West Peninsula.

Conflicts of interest/Competing interests: Adam Hampshire is owner and director of Future Cognition Ltd., a software company that produces bespoke cognitive assessment technology and that was paid to produce cognitive tasks for PROTECT.

Availability of material:

The data of this experiment can be found at <https://doi.org/10.17633/rd.brunel.24442468>

Supplementary Table 1 can be found at https://ins-inandpublish-prod.s3.fr-par.scw.cloud/papers/652519d3890bbf5b40a41e79/assets/Supplement_Table1_v2.xlsx

Supplementary Table 2 can be found at https://ins-inandpublish-prod.s3.fr-par.scw.cloud/papers/652519d3890bbf5b40a41e79/assets/Supplement_Table2_v2.xlsx

REFERENCES

- [1] Creese B, et al. (2023) **Late-life onset psychotic symptoms and incident cognitive impairment in people without dementia: modification by genetic risk for Alzheimer's disease** *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 9(2):e12386 <https://doi.org/10.1002/trc2.12386>
- [2] Ismail Z, Ghahremani M, Munir MA, Fischer CE, Smith EE, Creese B (2023) **A longitudinal study of late-life psychosis and incident dementia and the potential effects of race and cognition** *Nature Mental Health*, 1(4):273–283 <https://doi.org/10.1038/s44220-023-00043-x>
- [3] Liew TM (2020) **Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer's and non-Alzheimer's dementia** *Alzheimer's Research & Therapy*, 12(1):35 <https://doi.org/10.1186/s13195-020-00604-7>

- [4] Ismail Z, et al. (2017) **The Mild Behavioral Impairment Checklist (MBI-C): A rating scale for neuropsychiatric symptoms pre-dementia populations** *Journal of Alzheimer's Disease*, 56:929–938 <https://doi.org/10.3233/JAD-160979>
- [5] Ismail Z, et al. (2016) **Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment** *Alzheimer's & Dementia*, 12(2):195–202 <https://doi.org/10.1016/j.jalz.2015.05.017>
- [6] Stafford J, Dykxhoorn J, Sommerlad A, Dalman C, Kirkbride JB, Howard R (2021) **Association between risk of dementia and very late-onset schizophrenia-like psychosis: a Swedish population-based cohort study** *Psychological Medicine*, pp. 1–9 <https://doi.org/10.1017/S0033291721002099>
- [7] Creese B, et al. (2019) **Profile of Mild Behavioral Impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults** *International Psychogeriatrics*, <https://doi.org/10.31234/osf.io/jhx5k>
- [8] Creese B, Ismail Z (2022) **Mild Behavioral Impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer's disease** *Alzheimer's Research & Therapy*, 14(1):2 <https://doi.org/10.1186/s13195-021-00949-7>
- [9] Van Assche L, Morrens M, Luyten P, Van de Ven L, Vandenbulcke M (2017) **The neuropsychology and neurobiology of late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: A critical review** *Neuroscience and Biobehavioral Reviews*, 83:604–621 <https://doi.org/10.1016/j.neubiorev.2017.08.024>
- [10] Rajji TK, Mulsant BH (2008) **Nature and course of cognitive function in late-life schizophrenia: A systematic review** *Schizophrenia Research*, 102(1):122–140 <https://doi.org/10.1016/j.schres.2008.03.015>
- [11] MacKenzie LE, et al. (2017) **Hot and cold executive functions in youth with psychotic symptoms** *Psychological Medicine*, 47(16):2844–2853 <https://doi.org/10.1017/S0033291717001374>
- [12] Henik A, Salo R (2004) **Schizophrenia and the stroop effect** *Behavioral and Cognitive Neuroscience Reviews*, 3(1):42–59 <https://doi.org/10.1177/1534582304263252>
- [13] Woodrow A, Sparks S, Bobrovskaja V, Paterson C, Murphy P, Hutton P (2019) **Decision-making ability in psychosis: a systematic review and meta-analysis of the magnitude, specificity and correlates of impaired performance on the Iowa and Cambridge Gambling Tasks** *Psychological Medicine*, 49(1):32–48 <https://doi.org/10.1017/S0033291718002660>
- [14] Wolfova K, et al. (2022) **Gender/sex differences in the association of Mild Behavioral Impairment with cognitive aging** *Journal of Alzheimer's Disease*, 88:345–355 <https://doi.org/10.3233/JAD-220040>
- [15] Creese B, et al. (2019) **Mild Behavioral Impairment as a marker of cognitive decline in cognitively normal older adults** *The American Journal of Geriatric Psychiatry*, 27(8):823–834 <https://doi.org/10.1016/j.jagp.2019.01.215>

- [16] Stewart AL, Mills KM, King AC, Haskell WL, Gillis D, Ritter PL (2001) **CHAMPS physical activity questionnaire for older adults: outcomes for interventions** *Medicine & Science in Sports & Exercise*, 33(7) https://journals.lww.com/acsm-msse/fulltext/2001/07000/champs_physical_activity_questionnaire_for_older.10.aspx
- [17] Owen AM, et al. (2010) **Putting brain training to the test** *Nature*, 465(7299):775–778 <https://doi.org/10.1038/nature09042>
- [18] Epp AM, Dobson KS, Dozois DJA, Frewen PA (2012) **A systematic meta-analysis of the Stroop task in depression** *Clinical Psychology Review*, 32(4):316–328 <https://doi.org/10.1016/j.cpr.2012.02.005>
- [19] Rouse HJ, Small BJ, Schinka JA, Loewenstein DA, Duara R, Potter H (2021) **Mild Behavioral Impairment as a predictor of cognitive functioning in older adults** *International Psychogeriatrics*, 33(3):285–293 <https://doi.org/10.1017/S1041610220000678>
- [20] Taragano FE, et al. (2018) **Risk of conversion to dementia in a Mild Behavioral Impairment group compared to a psychiatric group and to a Mild Cognitive Impairment group** *Journal of Alzheimer's Disease*, 62(1):227–238 <https://doi.org/10.3233/jad-170632>
- [21] Liew TM (2019) **Symptom clusters of neuropsychiatric symptoms in Mild Cognitive Impairment and their comparative risks of dementia: A cohort study of 8530 older persons** *Journal of the American Medical Directors Association*, 20(8):1054.e1-1054.e9 <https://doi.org/10.1016/j.jamda.2019.02.012>
- [22] Rouse HJ, Ismail Z, Andel R, Molinari VA, Schinka JA, Small BJ (2023) **Impact of Mild Behavioral Impairment on longitudinal changes in cognition** *The Journals of Gerontology: Series A*, glad098 <https://doi.org/10.1093/gerona/glad098>
- [23] Yoon EJ, Lee J-Y, Kwak S, Kim YK (2023) **Mild behavioral impairment linked to progression to Alzheimer's disease and cortical thinning in amnesic mild cognitive impairment** *Frontiers in Aging Neuroscience*, 14 <https://doi.org/10.3389/fnagi.2022.1051621>
- [24] Davis KAS, et al. (2019) **Indicators of mental disorders in UK Biobank-A comparison of approaches** *International Journal of Methods in Psychiatric Research*, 28(3):e1796 <https://doi.org/10.1002/mpr.1796>
- [25] Linscott RJ, van Os J (2013) **An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders** *Psychological Medicine*, 43(6):1133–1149 <https://doi.org/10.1017/S0033291712001626>
- [26] Peters E, Garety P (2006) **Cognitive functioning in delusions: A longitudinal analysis** *Behaviour Research and Therapy*, 44(4):481–514 <https://doi.org/10.1016/j.brat.2005.03.008>
- [27] Orem DM, Bedwell JS (2010) **A preliminary investigation on the relationship between color-word Stroop task performance and delusion-proneness in**

nonpsychiatric adults *Psychiatry Research*, 175(1):27–32
<https://doi.org/10.1016/j.psychres.2008.09.001>

[28] Collerton D, et al. (2023) **Understanding visual hallucinations: A new synthesis** *Neuroscience and Biobehavioral Reviews*, 150:105208
<https://doi.org/10.1016/j.neubiorev.2023.105208>

[29] Catalan A, et al. (2021) **Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis: A Systematic Review and Meta-analysis** *JAMA Psychiatry*, 78(8):859-867 <https://doi.org/10.1001/jamapsychiatry.2021.1290>